Adaptimmune (NASDAQ: ADAP) just announced an upcoming data presentation at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer, or SITC. The company will present new data from its NY-ESO affinity enhanced T-cell therapy in patients with synovial sarcoma and myeloma, as well as data from preclinical safety assessments of its affinity enhanced T-cell therapy directed at MAGE A-10.
The presentations will take place at the McCormick Place exhibition center in National Harbor, MD on November 6, 2015 in the Prince George’s Exhibition Hall from 12:45 to 2:00 pm
The date has been added to the Binary Event Calendar.
Here's the release.